360 MASSACHUSETTS AVENUE, SUITE 203, ACTON, MA
Annual Meeting Held; Stockholders Approve Amendment to Stock Plan
Announces Closing of Up to $23.7 Million Private Placement Priced at-the-market Under Nasdaq Rules
Announce Strategic Partnership
Provides First Quarter 2026 Corporate Update
Announces Completion of 624 Patient Enrollments in SYMON-II Pivotal Clinical Trial
Bluejay Diagnostics Enters $125,000 Securities Purchase Agreement
Abstract Accepted for Presentation at the 2026 Society of Academic Emergency Medicine (SAEM) Annual Meeting
Provides Corporate Update and 2026 Strategic Outlook
Q1
FY 2025
Q3
Q2
Amended Annual Report
FY 2024
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Amended Schedule 13D - Ownership Report
Correspondence
Submission Upload
Prospectus Filed Pursuant to Rule 424(b)(1)